Almost fully funded, huge thanks to all our amazing investors!🔥🙌
Delee began seven years ago as an ambitious project that sought to understand how cancer disseminates through the body, by studying the process known as metastasis, which is responsible for 90% of cancer-related deaths. Unluckily, back then, there were not technologies with the necessary levels of performance to study this phenomenon. This forced us to form a team to develop from scratch all the technology necessary, to capture, enumerate, and analyze circulating tumor cells (CTCs) from patients’ blood samples.
Our team have worked through thousands of prototypes (no kidding😅) and countless hours of tough work, and have overcome hundreds of scientific, manufacturing, regulatory, and logistic challenges to get to where we are now🌟.
In the upcoming months, we will be finishing the commercial development of an exceptionally reliable and automated platform that can capture, enumerate, and analyze CTCs. This means that physicians will have the ability to early detect and precisely monitor the moment at which these cells began traveling through the circulation. In addition, a genetic analysis could be performed to the CTCs captured in order to get meaningful information, in a reliable, affordable, and constant way, with the aim to aid in the personalization of cancer therapies🔥.
We are deeply grateful for all the incredible support from all of you🙌. We wanted to say thanks for all the advice, connections, introductions, prayers, and encouraging words that we have received from all of you. There are no words to describe how deeply honored and grateful we are for that.
We also want to invite all those interested in taking advantage of these last days to invest, as we are surpassing 94% of the campaign final goal💪.
As you know, the world is going through difficult times, please stay safe, we will go through this together.
Again, thank you very much!
Delee Team💙
+1 956 662 4893
